Upgrade to SI Premium - Free Trial

Form SCHEDULE 13G CytomX Therapeutics, Filed by: BANK OF AMERICA CORP /DE/

August 3, 2026 12:05 PM





Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)




schemaVersion:


SCHEDULE 13G




Comment for Type of Reporting Person: The beneficial ownership calculation relies on the 217,702,919 outstanding shares disclosed in the Form 10-Q by the issuer on May 7, 2026, which reports share totals as of April 30, 2026.


SCHEDULE 13G



BANK OF AMERICA CORP /DE/
Signature:/s/ Monica Yako
Name/Title:Authorized Signatory
Date:08/03/2026

ATTACHMENTS / EXHIBITS

POWER OF ATTORNEY

Categories

SEC Filings